Frank Kalkbrenner

Frank is the Global Head of the Boehringer Ingelheim Venture Fund. He served as board member of STAT Diagnostica (acquired by Qiagen in 2018), Hookipa Biotech (IPO at NASDAQ in 2019), Amal Therapeutics (acquired by Boehringer Ingelheim in 2019), NBE Therapeutics (acquired by Boehringer Ingelheim in 2021) and a few more European biotechs. Currently, he is on the Boards of eTheRNA, Aelin Therapeutics, RinRi Therapeutics, and Acousia Therapeutics. Frank is a physician by training did his PhD in Pharmacology and specialized in Pharmacology and Toxicology. He spent more than 10 years in academic research in the Max-Planck-Institute for Molecular Genetics in Berlin and in the Institute of Pharmacology of the Freie Universität, Berlin. He began his industrial career at Schering AG and moved in 1999 to Boehringer Ingelheim joining Pulmonary Research. In 2005, he took over the responsibility for the Licensing Department. In this function, he was responsible for the licensing activities of the German Boehringer Ingelheim organization in various indication areas. In addition, he built up the Biological Research unit at the German Research site in Biberach. In 2010 – shortly after its initiation – Frank joined the Boehringer Ingelheim Venture Fund.